NEU 2.99% $20.10 neuren pharmaceuticals limited

Ann: Q2 2023 quarterly activity and cash flow report, page-11

  1. 127 Posts.
    lightbulb Created with Sketch. 35
    Yes, the four indications are excluded- and given that it is what Neuren wants to target it should have zero effect re valuations. Also, if Neuren wanted to go after another indication, I don't think it would be retrospective ie Acadia would surely have to have had commenced planning/trials at least?
 
watchlist Created with Sketch. Add NEU (ASX) to my watchlist
(20min delay)
Last
$20.10
Change
-0.620(2.99%)
Mkt cap ! $2.569B
Open High Low Value Volume
$20.41 $20.45 $19.92 $5.947M 296.0K

Buyers (Bids)

No. Vol. Price($)
1 999 $20.10
 

Sellers (Offers)

Price($) Vol. No.
$20.19 10 1
View Market Depth
Last trade - 16.10pm 25/07/2024 (20 minute delay) ?
NEU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.